VIRI (Virios Therapeutics, Inc.) Short-Term Debt to Capital

Virios Therapeutics (VIRI) develops innovative antiviral complexes to combat chronic fatigue syndrome and fibromyalgia. This price chart shows that Virios Therapeutics (VIRI) shares demonstrate a Separate Debt/Short Equity metric of 0.00. Business development relies on patent protection for treatment methods, while prolonged, costly trials and stringent regulatory oversight of therapy quality remain significant challenges.

Investors use this ratio to assess liquidity and short-term default risk by calculating the ratio of liabilities maturing within one year to total equity. The trend of current debt under one year relative to equity reflects the dependence of Virios Therapeutics (VIRI) on borrowed funds amid a lack of commercial revenue and total reliance on future patent protection for its drugs.